Drug intelligence / Profile preview

Lycobrain

Development stage: Unknown
Lead developer: Cambridge Diagnostic Imaging
Administration: Oral

Overview

Lycobrain is an oral nutraceutical dietary supplement developed by Cambridge Diagnostic Imaging to support brain health, cognitive and mental function, mood, and emotional balance. It is described as a first-in-class tissue-oxygenation support product and contains docosahexaenoic acid and carotenoids as active ingredients. Rather than acting as a conventional pharmaceutical against a defined molecular target, the product is intended to improve tissue oxygenation, particularly in the brain, and was positioned for use in aging, stress, and recovery from challenging conditions.

Brand names: LycobrainLycobrain Daily

Beyond the preview

Go deeper on Lycobrain.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lycobrain.

Explore the full profile